General and administrative (G&A) expenses were $12.4 million for the first quarter of 2025, which included $5.1 million of restructuring expenses in March 2025. Non-cash stock-based compensation ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its ...

We recently published a list of 13 Most Profitable Growth Stocks to Buy Now. In this article, we are going to take a look at ...

The growth factor in investing refers to companies that grow their revenue and earnings at rates significantly above the ...

Our partner, argenx, announced in April that the U.S. FDA approved VYVGART Hytrulo prefilled syringe, or PFS, for self-injection in generalized ... thyroid eye disease, myositis, seronegative ...

Registrational studies are currently ongoing in three subsets of myositis, thyroid eye disease (TED), and Sjögren’s disease. Topline results from ALKIVIA study evaluating three myositis subsets ...

Additional clinical updates include the expansion of Cabaletta’s trials into previously untapped areas such as juvenile myositis ... systemic sclerosis, and generalized myasthenia gravis.

For the first quarter, total revenues increased 9% to $8.1 billion in comparison to the first quarter of 2024. Product sales grew 11%, primarily driven by 14% ...